Pardoprunox (INN; code name SLV-308) is an antiparkinsonian drug developed by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued.http://adisinsight.springer.com/drugs/800014329 It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well.
Pardoprunox acts as a D<sub>2</sub> (pK<sub>i</sub> = 8.1) and D<sub>3</sub> receptor (pK<sub>i</sub> = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT<sub>1A</sub> receptor (pK<sub>i</sub> = 8.5) full agonist (IA = 100%). It also binds to D<sub>4</sub> (pK<sub>i</sub> = 7.8), ñ<sub>1</sub>-adrenergic (pK<sub>i</sub> = 7.8), ñ<sub>2</sub>-adrenergic (pK<sub>i</sub> = 7.4), and 5-HT<sub>7</sub> receptors (pK<sub>i</sub> = 7.2) with lower affinity. Relative to other dopaminergic antiparkinsonian agents, pardoprunox is thought to have significantly less of a propensity for inducing certain side effects like dyskinesia and psychosis.